

Michel Koole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/412812/publications.pdf>

Version: 2024-02-01

116
papers

3,284
citations

126907

33
h-index

182427

51
g-index

121
all docs

121
docs citations

121
times ranked

4202
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Study of the Pittsburgh Compound B Derivative ¹⁸ F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1251-1259.	5.0	273
2	Whole-Body Biodistribution and Radiation Dosimetry of ¹⁸ F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2009, 50, 818-822.	5.0	200
3	Bone scintigraphy with ^{99m} Tc-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 35-44.	3.0	129
4	^{99m} Tc-ECD brain perfusion SPET: variability, asymmetry and effects of age and gender in healthy adults. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 873-887.	2.1	108
5	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. <i>Molecular Imaging and Biology</i> , 2018, 20, 94-102.	2.6	88
6	Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1436-1441.	5.0	77
7	Calibration of gamma camera systems for a multicentre European ¹²³ I-FP-CIT SPECT normal database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1529-1540.	6.4	73
8	Preclinical Evaluation of ¹⁸ F-JNJ64349311, a Novel PET Tracer for Tau Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 975-981.	5.0	72
9	Quantifying SV2A density and drug occupancy in the human brain using [¹¹ C]UCB-J PET imaging and subcortical white matter as reference tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 396-406.	6.4	72
10	Preclinical Evaluation of ¹⁸ F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1584-1591.	5.0	64
11	Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [¹¹ C]-NE40 in Healthy Subjects. <i>Molecular Imaging and Biology</i> , 2013, 15, 384-390.	2.6	64
12	¹⁸ F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. <i>Journal of Nuclear Medicine</i> , 2019, 60, 683-690.	5.0	63
13	[¹⁸ F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [⁶⁸ Ga]Ga-DOTATATE in neuroendocrine tumour patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3033-3046.	6.4	59
14	In vivo synaptic density loss is related to tau deposition in amnesic mild cognitive impairment. <i>Neurology</i> , 2020, 95, e545-e553.	1.1	56
15	[¹¹ C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2051-2064.	6.4	55
16	A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox. <i>PLoS ONE</i> , 2015, 10, e0122363.	2.5	52
17	Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1977-1986.	3.9	52
18	Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients. <i>PLoS ONE</i> , 2015, 10, e0131486.	2.5	52

#	ARTICLE	IF	CITATIONS
19	Optimized In Vivo Detection of Dopamine Release Using ¹⁸ F-Fallypride PET. Journal of Nuclear Medicine, 2012, 53, 1565-1572.	5.0	49
20	Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 188-197.	6.4	48
21	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics, 2017, 4, 8.	2.7	46
22	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
23	⁶⁸ Ga-NOTA-Functionalized Ubiquitin: Cytotoxicity, Biodistribution, Radiation Dosimetry, and First-in-Human PET/CT Imaging of Infections. Journal of Nuclear Medicine, 2018, 59, 334-339.	5.0	44
24	Quantification of ¹⁸ F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test-Retest Study in Human Brain. Journal of Nuclear Medicine, 2013, 54, 1285-1293.	5.0	43
25	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. Journal of Nuclear Medicine, 2020, 61, 604-607.	5.0	42
26	Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1582-1594.	6.4	41
27	Experimental Performance Assessment of SPM for SPECT Neuroactivation Studies Using a Subresolution Sandwich Phantom Design. NeuroImage, 2002, 16, 200-216.	4.2	40
28	Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand ¹⁸ F-MK-9470 in Healthy Subjects. Journal of Nuclear Medicine, 2008, 49, 439-445.	5.0	38
29	Micro-Positron Emission Tomography Imaging of Rat Brain Metabolism during Expression of Contextual Conditioning. Journal of Neuroscience, 2012, 32, 254-263.	3.6	38
30	Pretargeted PET Imaging Using a Bioorthogonal ¹⁸ F-Labeled <i>trans</i> -Cyclooctene in an Ovarian Carcinoma Model. Bioconjugate Chemistry, 2017, 28, 2915-2920.	3.6	38
31	Regional Accuracy of ZTE-Based Attenuation Correction in Static [18F]FDG and Dynamic [18F]PE2I Brain PET/MR. Frontiers in Physics, 2019, 7, .	2.1	38
32	Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels-Alder reactions. Potential applications for pretargeted in vivo PET imaging. Chemical Science, 2017, 8, 1251-1258.	7.4	37
33	Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 254-261.	6.4	36
34	Transfer of normal 99mTc-ECD brain SPET databases between different gamma cameras. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 435-449.	2.1	33
35	Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of $\alpha_v\beta_3$ integrin expression. Journal of Nuclear Cardiology, 2015, 22, 1179-1186.	2.1	32
36	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of Nuclear Medicine, 2017, 58, 110-116.	5.0	31

#	ARTICLE	IF	CITATIONS
37	Synaptic density in healthy human aging is not influenced by age or sex: a ¹¹ C-UCB-J PET study. <i>NeuroImage</i> , 2021, 232, 117877.	4.2	31
38	Non-uniform versus uniform attenuation correction in brain perfusion SPET of healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 90-98.	2.1	30
39	Al ¹⁸ F-NOTA-octreotide: first comparison with ⁶⁸ Ga-DOTATATE in a neuroendocrine tumour patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2398-2399.	6.4	30
40	Validation of Parametric Methods for [¹¹ C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. <i>Molecular Imaging and Biology</i> , 2020, 22, 444-452.	2.6	28
41	Inflammation-Based Index and ⁶⁸ Ga-DOTATOC PET-â€Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰ Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1014-1020.	5.0	28
42	Preclinical evaluation of [¹⁸ F]MA3: a CB ₂ receptor agonist radiotracer for PET. <i>British Journal of Pharmacology</i> , 2019, 176, 1481-1491.	5.4	26
43	Translation of HDAC6 PET Imaging Using [¹⁸ F]EKZ-001â€cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1093-1101.	3.5	26
44	Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease. <i>Neurology</i> , 2022, 98, .	1.1	26
45	Non-invasive methods for absolute cerebral blood flow measurement using ^{99m} Tc-ECD: a study in healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 862-872.	2.1	25
46	Quantification and discriminative power of ¹⁸ F-FE-PE2I PET in patients with Parkinsonâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1913-1926.	6.4	24
47	¹¹ C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists. <i>Journal of Nuclear Medicine</i> , 2014, 55, 65-72.	5.0	23
48	Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [¹⁸ F]DPA-714 PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 163-172.	6.4	23
49	Synthesis and preclinical evaluation of [¹¹ C]MA-PB-1 for inâ€vivo imaging of brain monoacylglycerol lipase (MAGL). <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 104-113.	5.5	23
50	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1621-1627.	5.0	22
51	Preclinical Evaluation and Quantification of ¹⁸ F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1954-1959.	5.0	21
52	Preclinical Safety Evaluation and Human Dosimetry of [¹⁸ F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles. <i>Molecular Imaging and Biology</i> , 2020, 22, 173-180.	2.6	21
53	In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 0271678X2098150.	4.3	21
54	Inâ€vivo evidence for long-term vascular remodeling resulting from chronic cerebral hypoperfusion in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 726-739.	4.3	20

#	ARTICLE	IF	CITATIONS
55	Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer ¹⁸ F-FPEB in human brain. <i>Synapse</i> , 2016, 70, 153-162.	1.2	18
56	Preclinical Evaluation and Quantification of ¹⁸ F-Fluoroethyl and ¹⁸ F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A2A Receptor in Rat Brain. <i>Journal of Nuclear Medicine</i> , 2017, 58, 466-472.	5.0	18
57	Characterization of the novel GlyT1 PET tracer [¹⁸ F]MK6577 in humans. <i>Synapse</i> , 2015, 69, 33-40.	1.2	17
58	Endothelial Msx1 transduces hemodynamic changes into an arteriogenic remodeling response. <i>Journal of Cell Biology</i> , 2015, 210, 1239-1256.	5.2	17
59	Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. <i>Epilepsia</i> , 2018, 59, 959-970.	5.1	17
60	Local pulmonary drug delivery in the preterm rabbit: feasibility and efficacy of daily intratracheal injections. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L589-L597.	2.9	17
61	Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 68.	6.2	16
62	Distinct [¹⁸ F]THK5351 binding patterns in primary progressive aphasia variants. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2342-2357.	6.4	16
63	Clinical validation of the novel HDAC6 radiotracer [¹⁸ F]EKZ-001 in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 596-611.	6.4	16
64	Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [¹⁸ F]FDG and [¹⁸ F]FECT Functional Mapping of the Mouse Brain. <i>PLoS ONE</i> , 2013, 8, e65286.	2.5	16
65	Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. <i>Nuclear Medicine and Biology</i> , 2014, 41, 695-704.	0.6	15
66	Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2681-2690.	6.4	15
67	Cross-Modal Distillation to Improve MRI-Based Brain Tumor Segmentation With Missing MRI Sequences. <i>IEEE Transactions on Biomedical Engineering</i> , 2022, 69, 2153-2164.	4.2	15
68	Spatial decrease of synaptic density in amnesic mild cognitive impairment follows the tau build-up pattern. <i>Molecular Psychiatry</i> , 2022, 27, 4244-4251.	7.9	15
69	[¹⁸ F]JN42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. <i>Journal of Neurochemistry</i> , 2016, 139, 897-906.	3.9	14
70	Evaluation of androgen-induced effects on the uptake of [¹⁸ F]FDG, [¹¹ C]choline and [¹¹ C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. <i>EJNMMI Research</i> , 2013, 3, 31.	2.5	13
71	Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 1, 3.	3.9	13
72	Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. <i>Scientific Reports</i> , 2021, 11, 15981.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Changes in synaptic density in the subacute phase after ischemic stroke: A ¹¹ C-UCB-J PET/MR study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, , 0271678X2110477.	4.3	12
74	Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. <i>International Journal of Oncology</i> , 2014, 44, 819-829.	3.3	11
75	Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. <i>PLoS ONE</i> , 2016, 11, e0149955.	2.5	11
76	Prospective comparison of simultaneous [⁶⁸ Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. <i>European Radiology</i> , 2022, 32, 901-911.	4.5	11
77	Three-dimensional rotational angiography fused with multimodal imaging modalities for targeted endomyocardial injections in the ischaemic heart. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 900-907.	1.2	10
78	Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 664-680.	6.4	10
79	The PET tracer [¹¹ C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. <i>Science Translational Medicine</i> , 2022, 14, eabg3684.	12.4	10
80	Impact of meningeal uptake and partial volume correction techniques on [¹⁸ F]MK-6240 binding in aMCI patients and healthy controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1236-1246.	4.3	10
81	Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 943-945.	3.9	9
82	A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [¹⁸ F]MK-6240. <i>EJNMMI Research</i> , 2021, 11, 49.	2.5	9
83	The geometric transfer function for a slat collimator mounted on a strip detector. <i>IEEE Transactions on Nuclear Science</i> , 2005, 52, 708-713.	2.0	8
84	Convolutional Neural Networks for Brain Tumor Segmentation Using Different Sets of MRI Sequences. , 2019, , .		8
85	Pharmacokinetic modeling of [¹¹ C]flumazenil kinetics in the rat brain. <i>EJNMMI Research</i> , 2017, 7, 17.	2.5	7
86	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. <i>EJNMMI Research</i> , 2018, 8, 110.	2.5	7
87	Monte Carlo Simulations of the GE Signa PET/MR for Different Radioisotopes. <i>Frontiers in Physiology</i> , 2020, 11, 525575.	2.8	7
88	Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 265-277.	0.7	7
89	Imaging of cardiac and renal perfusion in a rat model with ¹³ N- ¹⁵ NH ₃ micro-PET. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 213-219.	1.5	6
90	Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [¹⁸ F]JNJ-64413739 PET and MRA-driven image derived input function. <i>Scientific Reports</i> , 2021, 11, 16172.	3.3	6

#	ARTICLE	IF	CITATIONS
91	Cognitive Decline Assessment: A Review From Medical Imaging Perspective. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704661.	3.4	6
92	Parametric Imaging of [¹¹ C]Flumazenil Binding in the Rat Brain. <i>Molecular Imaging and Biology</i> , 2018, 20, 114-123.	2.6	5
93	Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson's disease using ¹⁸ F-FDG PET imaging. <i>Scientific Reports</i> , 2019, 9, 12368.	3.3	5
94	Study of the quantification of FBP SPECT images with a correction for partial volume effects. <i>IEEE Transactions on Nuclear Science</i> , 2002, 49, 69-73.	2.0	4
95	Asymmetric Amyloid Deposition in the Brain Following Unilateral Electroconvulsive Therapy. <i>Biological Psychiatry</i> , 2017, 81, e11-e13.	1.3	4
96	Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [¹⁸ F]DPA-714 PET imaging of the rat brain. <i>EJNMMI Research</i> , 2018, 8, 112.	2.5	4
97	Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets. <i>Bioconjugate Chemistry</i> , 2021, 32, 2052-2064.	3.6	4
98	Preclinical Evaluation of [¹¹ C]YC-72-AB85 for In Vivo Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3915-3927.	3.5	4
99	Influence of detector thickness on resolution in three-headed gamma camera PET. <i>IEEE Transactions on Nuclear Science</i> , 2002, 49, 98-103.	2.0	3
100	Fluoro-D-glucose-micro positron emission tomography as a diagnostic tool to confirm brain death in a murine donor lung injury model. <i>Journal of Surgical Research</i> , 2013, 180, 343-348.	1.6	3
101	Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [¹⁸ F]-FDOPA brain PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3124-3134.	4.3	3
102	[¹¹ C]Pae150: [¹¹ C]MK6884 PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORS-TREATED AD PATIENTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P121.	0.8	3
103	Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome. <i>Radiology Imaging Cancer</i> , 2021, 3, e200061.	1.6	3
104	Human biodistribution and dosimetry of [¹¹ C]-UCB-J, a PET radiotracer for imaging synaptic density. <i>EJNMMI Physics</i> , 2021, 8, 37.	2.7	3
105	Abstract OT2-1-10: RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study. , 2015, , .		3
106	Twelve-Week Yoga vs. Aerobic Cycling Initiation in Sedentary Healthy Subjects: A Behavioral and Multiparametric Interventional PET/MR Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 739356.	2.6	3
107	Transmission imaging with a moving point source: influence of crystal thickness and collimator type. <i>IEEE Transactions on Nuclear Science</i> , 2005, 52, 166-173.	2.0	2
108	Dual time-point imaging for post-dose binding potential estimation applied to a [¹¹ C]raclopride PET dose occupancy study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 866-876.	4.3	2

#	ARTICLE	IF	CITATIONS
109	The Effect of Aging on Brain Glucose Metabolic Connectivity Revealed by [18F]FDG PET-MR and Individual Brain Networks. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 798410.	3.4	2
110	Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study. <i>Addiction Biology</i> , 2022, 27, e13167.	2.6	2
111	[18F]JNJ41510417 a potential PET radioligand for imaging phosphodiesterase-10A in the brain. <i>NeuroImage</i> , 2010, 52, S15.	4.2	0
112	Low-dose CT-derived attenuation scan: One acquisition, more applications?. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 429-430.	2.1	0
113	An approach for a reconstruction-derived whole-blood arterial input function (RDIF) in PET/MRI. , 2018, , .		0
114	Regional distribution of amyloid deposition and grey matter atrophy in late-life depression. <i>Alzheimer's and Dementia</i> , 2020, 16, e041564.	0.8	0
115	PET Quantification in Neuropsychiatry. , 2014, , 15-44.		0
116	Glucose metabolism changes in cerebellar tonsils as an early predictor of cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0